Hexahydrocannabiphorol
Semi-sythetic cannabinoid drug
From Wikipedia, the free encyclopedia
Commonly misspelled as 'hexahydroxycannabiphorol'
| |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C23H36O2 |
| Molar mass | 344.539 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Hexahydrocannabiphorol (HHCP) is a semi-synthetic cannabinoid derivative which has been marketed since around 2021.[1][2] It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019.[3] HHCP was studied by Roger Adams as early as 1942.[4]
Pharmacology
HHC-P is a partial agonist of the CB1 receptors with an EC50 of 44.4nM for 9R-HHCP and 134nM for 9S-HHCP. Compared to Hexahydrocannabinol (HHC) with an EC50 of 101nM for 9R-HHC and 1,190nM for 9S-HHC.[5] In 2021, HHC-P was positively identified in multiple gray market cannabis products in the United States.[1]
Legality
The legal status of hexahydrocannabinol and derivatives varies between countries, leading to widespread sale in some parts of Europe and the US.
In France, HHCP was banned in 2023.[6]
In Japan, Japanese Health Ministry announced that six synthetic cannabinoids with structures similar to HHCH, including HHCP, were to be banned from 6 January 2024.[7]
HHCP was banned in Slovakia as of 13 January 2024.[citation needed]
